EGFR

Xiaohua Pan1, Jianya Zhang2, Chao Ye2

  • 1School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China.

Frontiers in oncology
|December 12, 2025
PubMed
まとめ

複数の治療に抵抗性を示す進行したEGFR遺伝子変異陽性肺癌患者が、新規PD-1/VEGF-A二重特異性抗体であるイボネシマブに対し迅速に奏効した。これは、治療困難な非小細胞肺癌(NSCLC)の耐性克服におけるその可能性を強調するものである。

関連する概念動画

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K